Direction Of Travel Of EU HTA Regulation Is ‘Disappointing’ For Advanced Therapies
Executive Summary
Without further work, the EU-wide joint clinical assessments introduced by the EU regulation on health technology assessments will fail to meet the needs of advanced therapies, warns the Alliance for Regenerative Medicine.
You may also be interested in...
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.
Expanding Hospital Exemptions For ATMPs Could Make Europe Less Attractive To Investors
The forthcoming overhaul of the EU pharma legislation should not include an expansion of the hospital exemption provision for advanced therapies, warn industry and regulators.
EMA Launches First RWE Studies Under Big Data Project
The European Medicines Agency has partnered with eight institutions having access to real-world healthcare data to enable its DARWIN EU project to deliver real-world evidence to the EU medicines regulatory network when needed.